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Background: According to the humor theory of Traditional Uighur Medicine (TUM), a same disease is classified into
different abnormal humor types and corresponding methods are applied to treat the diseases according to the
type of abnormal humor characteristics. To date the biological foundation of classification of diseases by humor
theory has been little studied and the mechanism of action is still unclear. In the present study, we aimed to
investigate the association between some related gene polymorphisms and depression with abnormal humor
in TUM.
Methods: 201 cases of depression patients in a Uighur population were divided into two groups as: 107 cases of
depression patients with abnormal black bile (ABB), 94 cases of depression patients with none abnormal black bile
(nABB), and 50 healthy people were served as control group. Venous blood was used to isolate DNA samples, and
the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique was used for
genotyping of single nucleotide polymorphisms (SNPs). Polymorphisms in the serotonin 2A (5-HT2A) receptor gene,
brain derived neurotrophic factor (BDNF), serotonin 1A (5-HT1A) receptor gene were investigated in each groups,
respectively.
Results: The 5-HT2A A-1438G, 5-HT2A T102C, BDNF Val66Met, and 5-HT1A C-1019G gene polymorphisms showed
significant association with ABB. However, no difference between nABB and controls was found for those genotype
distribution and allele frequency. Moreover, the T102C and A1438G SNPs in the 5-HT2A receptor gene polymorphisms
were in linkage disequilibrium. In addition, the OR associated with the combination of Val66Met-Val/Val genotype plus
the presence of -1019C allele was 8.393 for ABB compared with controls (OR 8.393; 95% CI 1.807 ~ 38.991; P= 0.003).
Moreover, the OR associated with the presence of -Met plus -1019C alleles was 12.194 for ABB compared with controls
(OR 12.194; 95% CI 1.433 ~ 103.776; P= 0.005). The OR associated with the presence of -1438C/C plus Val/Val genotypes
was 7.738 for ABB compared with controls (OR 7.738; 95% CI 1.566 ~ 38.241; P= 0.005).
Conclusion: It was concluded that there were significant relationship between the gene polymorphisms and
classification of depression with abnormal humor in TUM. The 5-HT2A A-1438G, 5-HT2A T102C, BDNF Val66Met, and
5-HT1A C-1019G gene polymorphisms might predict the incidence of depression with ABB.
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Depression is a major public health problem. It tends to
have a chronic course, produces disability and is associ-
ated with suicide [1,2]. There are overwhelming justifica-
tions to explore the molecular mechanisms underlying
major depressive disorder [3], depression significantly
complicates chronic illness [4] and depression is the
leading cause of disability worldwide [5].
The disease of depression or melancholy (black bile in
Greek) was linked to the Hippocratic/Galenic medical
theory of the four humors. Humoral Theory was initially
Greek philosophy and firstly brought to medicine by
Hippocrates (c.460-370 B.C.), adopted and developed by
Greek (e.g. Galen, c.129-216 A.D.), Roman and Islamic
physicians (e.g. Avicenna, c.980-1037 A.D.), it became
the most commonly held view of the human body
among European physicians until the discoveries of the
functions of the circulatory, respiratory and digestive
systems in 18th century. Essentially, this theory holds
that human body was filled with four basic substances or
humors- blood, phlegm, yellow bile and black bile. Ac-
cording to Hippocrates Medicine, the four humors
needed to be balanced for good health, and an excess or
deficit of one of these humors would disrupt the balance
of these humors and cause disease [6]. “Abnormal black
bile” is the term for an excess of black bile (literally
“savda” in Arabic) and Melancholia or Depression was
thought to be caused by “Abnormal black bile” by Galen
which was adopted by Avicenna [7,8]. Although exist-
ence of black bile or abnormal black bile in body has
never been confirmed in modern research, the demon-
strated symptoms and signs of abnormal black bile were
described in detail in Cannon of Medicine by Avicenna
[9]. Although the four humors theory was dismantled
from 19th century, the definitive methods of Hippocratic
medicine clinical diagnostics of abnormal humors have
survived intact in the medical system of Uighur people
in China. Traditional Uighur Medicine (TUM) considers
the unbalanced humors or abnormal changes of humors
are thought to cause disorders or diseases, and most
clinical works identified the cause of complex diseases
such as cancer, depression as an excess of black bile
[10-12]., and some researches even indicate patients with
“abnormal black bile” were significantly different from
those with “non-abnormal black bile” (abnormal blood,
yellow bile and phlegm) in terms of gene polymorphism,
pre-thrombotic state and oxidative stress [13-15]. How-
ever, is “abnormal black bile” an existing phenomenon
with distinct biological basis or merely imaginary philo-
sophical concept that causes Depression? We undertook
this investigation to answer this question.
The 5-HT2A receptor is widely distributed in the
central nervous system and periphery, and associated
with major depressive illness [16]. Two single nucleotidepolymorphisms, A-1438G and T102C are common in
the population, show strong linkage disequilibrium with
depression, and are associated with efficacy and positive
side effect profiles of anti-depressant medications in
some studies [17-20]. The 5-HT1A receptor is a key
mediator of serotonergic signaling in the central nervous
system, and known as the major autoreceptor of seroto-
nergic raphe neurons [21]. The C-1019G polymorphism
of the 5-HT1A gene promoter polymorphism affects 5-
HT1A receptor binding potential and protein expression
[22]. Several studies suggest that GG genotype or G
allele carriers of the 5-HT1A gene promoter polymorph-
ism have a greater risk of depression and poorer response
to antidepressant therapy [18,22]. Brain-derived neuro-
trophic factor (BDNF) plays a critical role in neuronal
growth, survival and differentiation neuronal cells of the
central nervous system [23]. There is increasing evidence
that the BDNF might be one of the relevant factors in the
pathophysiology of depression [24]. Evidence of an asso-
ciation between the BDNF Val66Met polymorphism and
depression is rapidly being replicated [25].
In the present study, we investigated the 5-HT2A
T102C, 5-HT2A A-1438G, BDNF Val66Met and 5-HT1A
C-1019G gene polymorphisms in depression patients
with two type of abnormal humor in TUM. Some of
these gene polymorphisms have been thoroughly stud-
ied, but to our knowledge this is the first study to inves-
tigate the association of multiple polymorphisms and
depression with abnormal humor in TUM. Our purpose
was to investigate the association between some related
gene polymorphisms and depression with abnormal
humor, and whether certain genetic polymorphisms may
be predictive markers of depression in patients with




Patients including in this study met standards both of
Western medicine and Traditional Uighur medicine.
Specially, we followed the following criteria: (a) Uighur
ethnic group, (b) aged 14 to 80 years, (c) meet the Mood
disorder standard of Chinese Classification of Mental
Disorders (CCMD-3), (d) the Hamilton Rating Scale for
Depression (HAMD) 24-item version scale score ≥ 18,
(e) patients or their parents gave informed consent for
this study, and (f ) there were no restrictions on gender.
We excluded patients: (a) with cerebrovascular disease
or other serious organic brain diseases, (b) with high
blood pressure, diabetes and other serious physical illness,
(c) with other mental disorders associated with depression,
(d) who has a history of manic episodes or anti-depressant
induced mania, (e) who recently (within six weeks) re-
ceived anti-depressant treatment.
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We selected 201 patients of Uighur population who were
diagnosed by two independent psychiatrists respectively
(134 females and 67 males mean age 42.57 ± 15.64 years).
While 50 healthy volunteers were used as controls (20
females and 30 males with a mean age of 28 ± 8.56 years).
The research protocol was approved by the First Affiliated
Hospital (First Affiliated Hospital, Xinjiang Medical Uni-
versity, Urumqi, China) ethics review committee. Written
informed consent was obtained from each subject prior to
the study.
Classification of depression by TUM
201 cases of depression patients were classified into
abnormal black bile (ABB) group and none abnormal
black bile (nABB) group according to humor classifi-
cation criteria described in TUM [9,10]. The ABB group
consisted of 72 females and 35 males with a mean age of
44.19 ± 15.43 years and with a mean HAMD score of
37.92 ± 11.53. The nABB group consisted of 62 females
and 32 males with a mean age of 40.65 ± 16.68 years and
with a mean HAMD score of 38.42 ± 13.59.
DNA analysis and genotyping
DNA preparation
After 12 hours of fasting, 4 ml of venous blood was col-
lected from each subject in 0.019 mol/L sodium citrate
(1 portion anticoagulant + 9 portion whole blood). DNA
was extracted from blood leukocytes with the TIANamp
Blood DNA Kit (TIANGEN BIOTECH, Beijing).
5-HT2A genotyping
To genotype the A-1438G SNP in the 5-HT2A gene,
PCR was performed with the forward primer 5′-
CTAGCCACCCTGAGCCTATG-3′ and the reverse pri-
mer 5′-TTGTGCAGATTCCCATTAAGG-3′. The amp-
lification mixture contained 2 μl of 100 ng/μl DNA,
10 μl of 2 ×Master Mix (2 × Taq PCR Master Mix,
TIANGEN), 0.5 μl of 20 μM each primer, 7 μl of distilled
water in a final volume of 20 μl. The amplification cycle
was performed on a C1000™ Thermal Cycler (BIO-RAD,
USA). After an initial denaturation at 94°C for 3 min, the
DNA was amplified by 35 PCR cycles: denaturation at
94°C for 30 s, annealing at 58.1°C for 30 s and extension
at 72°C for 1 min, followed by a final extension at 72°C for
7 min, and the reaction was terminated at 4°C. Amplified
products were separated by electrophoresis on 1.5% agar-
ose gel and visualized with ultraviolet light after ethidium
bromide staining. The 2 ×Master Mix contained 10 mM
Tris–HCl (PH8.3), 100 mM KCl, 3 mM MgCl2, 500 μM
dNTP each, 0.1 U Taq Polymerase/μl. The amplified DNA
was digested at 37°C for 12 hours with the restriction
enzyme MspI (Fermentas, USA), which cuts at the 1438G
site. The product was electrophoresed on 3% agarose gelsand stained with ethidium bromide. Homozygous geno-
types were identified by the presence of a single 200-bp
band (AA), or bands of 121- and 79-bp (GG). The hetero-
zygous genotype (AG) had all three bands.
To genotype the T102C SNP in the 5-HT2A gene, PCR
was performed with the forward primer 5′-TCTGCTA-
CAAGTTCTGGCTT-3′ and the reverse primer 5′-
CTGCAGCTTTTTCTCTAGGG-3′ [26]. Amplification
was performed using the same methods described for
the 5-HT2A A-1438G SNP. Allele 1 (T102-allele) was
represented by the uncut 342-bp PCR product and allele
2 (C102-allele) consisted of two fragments at 217- and
125-bp.
BDNF genotyping
The genotyping of Val66Met polymorphism of the
BDNF gene was determined by examining the occur-
rence of a NlaIII recognition site [27]. The PCR assay
mixture contained 2 μl of 100 ng/μl DNA, 10 μl of 2 ×
Master Mix (2 × Taq PCR Master Mix, TIANGEN), 0.5 μl
of 20 μM each primer (5′-ACTCTGGAGAGCGTGAAT-
3′ and 5′-ATACTGTCACACACGCTC-3′) [28], and 7 μl
of distilled water. The amplification cycle was performed
on a C1000™ Thermal Cycler (BIO-RAD, USA). After an
initial denaturation at 94°C for 5 min, the DNA was amp-
lified by 35 cycles: denaturation at 94°C for 30 s, annealing
60°C for 30 s and extension 72°C for 1 min, followed by a
final extension at 72°C for 7 min, the reaction was termi-
nated at 4°C. PCR products were digested with NlaIII
(Fermentas, USA) endonuclease, the product was electro-
phoresed on 3% agarose gels and stained with ethidium
bromide. The presence of 168 and 75 bp bands indicates
the existence of A (Met) allele; the presence of 243 bp
band indicates the existence of G (Val) allele, while the
presence of 75, 168 and 243 bp indicates AG (Met/Val)
heterozygote.
5-HT1A genotyping
To genotype the C-1019G SNP in the 5-HT1A gene, PCR
was performed with the forward primer 5′-TGGAAGAA
GACCGAGTGTGTCTAC-3′ and the reverse primer 5′-
TTCTCCCTGAGGGAGTAAGGCTGG-3′ [29]. The am-
plification mixture contained 2 μl of 100 ng/μl DNA,
10 μl of 2 ×Master Mix (2 × Taq PCR Master Mix, TIAN-
GEN), 0.5 μl of 20 μM each primer and 7 μl of distilled
water. Samples were amplified using a C1000™ Thermal
Cycler (BIO-RAD, USA) for 36 cycles. After an initial
5 min at 95°C, each cycle consisted of 45 s at 95°C, 45 s at
56°C, and 45 s at 72°C. After a final 10 min at 72°C, the
reaction was terminated at 4°C. The amplified DNA
was digested with the restriction enzyme Hpy CH4IV
(Fermentas, USA ), which cuts at the -1019G site, and the
product was electrophoresed in 5% agarose gels and
stained with ethidium bromide. Homozygous genotypes
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(C/C), or bands of 158 and 24 bp (G/G). The heterozygous
genotype had three bands: 182, 158, and 24 bp (C/G).
Statistical analysis
Data was analyzed using the statistical package for social
sciences (SPSS ver.17). Quantitative variables were
expressed as mean ± SD. Differences in variable means
between ABB group and nABB group were compared by
T test. Reported percentages reflect average values.
Alleles, genotype frequencies, and individual features
between patients and control subjects were compared by
Pearson Chi-Square (χ2) and Continuity Correction Chi-
Square test. Hardy-Weinberg equilibrium was assessed




Homozygous genotypes were identified by the presence of
a single 200-bp band (AA) or bands of 121- and 79-bp
(GG). The heterozygous type (AG) displayed all three
band sizes (Figure 1).
The distribution of the A-1438G polymorphism of 5-
HT2A in nABB group and control group were in agree-
ment with the Hardy-Weinberg equilibrium. There were
no significant differences between groups (P > 0.05). The
Hardy-Weinberg equilibria for the candidate gene were
as follows: nABB group, χ2= 0.095, df= 2, P= 0.954; control
group, χ2= 0.665, df= 2, P= 0.717.
Frequencies of 5-HT2A A-1438G alleles and genotypes
in the ABB group, nABB group and control group are
shown in Table 1. There were significant differences in
the 5-HT2A A-1438G genotype distributions among the
ABB group,nABB group and control group (χ2= 13.310,
P= 0.010). Compared with the control and nABB groups,Figure 1 Agarose gel eletrophoretogram of 5-HT2A A-1438G PCR prod
polymorphism of 5-HT2A in nABB group and control group were in agreem
differences between groups (P > 0.05). Lane M1: 50 bp DNA Ladder; Lane A
2000 bp DNA marker.the ABB group had significant differences (χ2= 12.760,
P= 0.002; χ2= 8.299, P= 0.016) in the A-1438G genotype
distributions. Compared to control group, the nABB
group had not a significant difference in the A-1438G
genotype distributions (P > 0.05). Individuals with the
GG (OR 0.176; 95% CI 0.057 ~ 0.538) genotypes were
more likely to not have depression. Moreover, GG geno-
type seemed to be protective factor. There were no
significant differences in the 5-HT2A A-1438G allele
distributions among the ABB group,nABB group and
control group (χ2= 1.904, P= 0.386).
5-HT2A T102C polymorphism
Homozygous genotypes were identified by the presence of
a single 342-bp band (TT), or bands of 217- and 125-bp
(CC). The heterozygous genotype (TC) had all three bands
(Figure 2).
The distribution of the 5-HT2A T102C polymorphism
in nABB group and control group were in agreement
with the Hardy-Weinberg equilibrium. There were no
significant differences between groups (P > 0.05).The
Hardy-Weinberg equilibria for the candidate gene were
as follows: nABB group χ2= 0.096 df= 2 P= 0.953; control
group χ2= 0.675 df= 2 P= 0.714.
Frequencies of the 5-HT2A T102C alleles and geno-
types in the ABB group, nABB group and control group
are shown in Table 1. There were significant statistical
differences in the 5-HT2A T102C genotype distributions
among the ABB group, nABB group, and control group
(χ2= 15.686, P= 0.003). Compared with the control and
nABB groups, the ABB group had significant differences
(χ2= 15.602, P= 0.000; χ2= 9.074, P= 0.011) in the T102C
genotype distributions. Compared to control group, the
nABB group had not a significant difference (P > 0.05) in
the T102C genotype distributions. Individuals with the
CC (OR 0.139; 95% CI 0.042 ~ 0.463) genotypes wereuct after digestion with MspI. The distribution of the A-1438G
ent with the Hardy-Weinberg equilibrium. There were no significant
, D, and G: AA; Lane B, E, and H: GG; Lane C, F, and I: AG; Lane M2:
Table 1 5-HT2A A-1438G, 5-HT2A T102C, BDNF Val66Met, and 5-HT1A C-1019G genotype and allele distribution in
depression patients and controls
Genotype
and allele
ABB group (n= 106) nABB group (n= 89) Control group (n= 50) χ2 P value
n (%) n (%) n (%)
5-HT2A A-1438G
Genotype AA 34(32.1) 29(32.6) 18(36.0) 13.31 0.01
AG 67(63.2) 45(50.6) 21(42.0)
GG 5(4.7) 15(16.9) 11(22.0)
P value 0.002a 0.59
Alleles A 135(63.7) 103(57.9) 57(57.0) 1.9 0.39
G 77(36.3) 75(42.1) 43(43.0)
P value 0.26 0.89
5-HT2A T102C
Genotype TT 34(32.1) 30(33.7) 19(38.0) 15.69 0
TC 68(64.2) 45(50.6) 20(40.0)
CC 4(3.8) 14(15.7) 11(22.0)
P value 0.000b 0.44
Alleles T 136(64.2) 105(59.0) 58(58.0) 1.57 0.46
C 76(35.8) 73(41.0) 42(42.0)
P value 0.3 0.87
BDNF Val66Met
Genotype Val/Val 51(48.1) 35(39.3) 12(24.0) 17.79 0
Met/Val 51(48.1) 42(47.2) 26(52.0)
Met/Met 4(3.8) 12(13.5) 12(24.0)
P value 0.040c 0.11
Alleles Val 153(72.2) 112(63.0) 50(50.0) 14.77 0
Met 59(27.8) 66(37.0) 50(50.0)
P value 0.000d 0.04
5-HT1A C-1019G
Genotype CC 46(43.4) 40(45.0) 15(30.0) 14.63 0.01
CG 55(51.9) 35(39.3) 23(46.0)
GG 5(4.7) 14(15.7) 12(24.0)
P value 0.001e 0.19
Alleles C 147(69.3) 115(64.6) 53(53.0) 7.91 0.02
G 65(30.7) 63(35.4) 47(47.0)
P value 0.005f 0.06
aOdds ratio (and 95% confidence interval) for GG vs (A/G + A/A) is 0.176(0.057 ~ 0.538), χ2= 11.O25, df= 1, P= 0.001.
bOdds ratio (and 95% confidence interval) for CC vs (T/C + T/T) is 0.139(0.042 ~ 0.463), χ2= 12.987, df= 1, P= 0.000.
cOdds ratio (and 95% confidence interval) for Val/Val vs (Val/Met + Met/Met) is 2.936(1.383 ~ 6.232), χ2= 8.205, df= 1, P= 0.004, and Met/Met vs Val/Met + Val/Val is
0.124(0.038 ~ 0.409), χ2= 15.100, df= 1, P= 0.000.
dOdds ratio (and 95% confidence interval) for Met allele vs Val allele is 2.936(1.383 ~ 6.232), χ2= 14.692, df= 1, P= 0.000.
eOdds ratio (and 95% confidence interval) for GG vs (G/C + C/C) is 0.157(0.052 ~ 0.475), χ2= 13.010, df= 1, P= 0.000.
fOdds ratio (and 95% confidence interval) for C allele vs G allele is 2.006(1.229 ~ 3.271), χ2= 7.884, df= 1, P= 0.005.
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genotype seemed to be protective factor. There were no
significant differences in the 5-HT2A T102C allele
distributions among the ABB,nABB and control group
(χ2= 1.566, P= 0.457).BDNF Val66Met polymorphism
Homozygous genotypes were identified by the presence
of a single 243-bp band (Val/Val), or bands of 75- and
168-bp (Met/Met). The heterozygous genotype (Met/Val)
had all three bands (Figure 3).
Figure 2 Agarose gel eletrophoretogram of 5-HT2A T102C PCR product after digestion with MspI. The distribution of the 5-HT2A T102C
polymorphism in nABB group and control group were in agreement with the Hardy-Weinberg equilibrium. There were no significant differences
between groups (P > 0.05). Lane M1: 2000 bp DNA marker; Lane A, D, and G: TT; Lane B, E, and H: CC; Lane C, F, and I: TC; Lane M2: 50 bp
DNA Ladder.
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in the ABB group, nABB group and control group were in
agreement with the Hardy-Weinberg equilibrium. There
were no significant differences between groups (P > 0.05).
The Hardy-Weinberg equilibria for the candidate gene
were as follows: ABB group, χ2= 2.165,df= 2, P= 0.339;
nABB group, χ2= 0.006,df= 2, P= 0.997; control group,
χ2= 0.090,df= 2, P= 0.956.
The genotype and allele frequency distributions of
BDNF Val66Met polymorphism in patients and control
subjects is shown in Table 1. There were significant
statistical differences in the BDNF Val66Met genotype
distributions among the ABB group, nABB group, and
control group (χ2= 17.793, P= 0.001). Compared with the
control and nABB groups, the ABB group had significant
differences (χ2= 6.414, P= 0.040; χ2= 18.547, P= 0.000) in
the BDNF Val66Met genotype distributions. Compared
to control group, the nABB group had not a significant
difference (P > 0.05) in the Val66Met genotype distribu-
tions. Individuals with the Met/Met (OR 0.124; 95% CI
0.038 ~ 0.409) genotypes were more likely to not have
depression. Moreover, Met/Met genotype seemed to be
protective factor. In case of the genotypic association of
BDNF, analyses using the recessive model showedFigure 3 Agarose gel eletrophoretogram of BDNF Val66Met PCR prod
Val66Met polymorphism in the ABB group, nABB group and control group
no significant differences between groups (P > 0.05). Lane M1: 50 bp DNA
and I: Met/Val; Lane M2: 50 bp DNA Ladder.association between the SNP and the risk of depression
(χ2= 8.205,P= 0.004). Individuals with the Met allele
more likely to be have depression (OR 2.936; 95% CI
1.383 ~ 6.232 for the recessive model). There were sig-
nificant differences in the BDNF Val66Met allele dis-
tributions among the ABB,nABB and control group
(χ2= 14.773, P= 0.001).
5-HT1A C-1019G polymorphism
Homozygous genotypes were identified by the presence of
a single 182-bp band (C/C), or bands of 24- and 158-bp
(G/G). The heterozygous genotype (C/G) had all three
bands (Figure 4).
The distribution of the 5-HT1A C-1019G polymorphism
in the ABB group, nABB group and control group were in
agreement with the Hardy-Weinberg equilibrium. There
were no significant differences between groups (P > 0.05).
The Hardy-Weinberg equilibria for the candidate gene
were as follows: ABB group, χ2= 2.924,df= 2, P= 0.232;
nABB group, χ2= 0.951,df= 2, P= 0.622; control group,
χ2= 0.161,df= 2, P= 0.923.
The genotype and allele frequency distribution of
5-HT1A C-1019G polymorphism in patients and control
subjects is shown in Table 1. There were significantuct after digestion with NlaIII. The distribution of the BDNF
were in agreement with the Hardy-Weinberg equilibrium. There were
Ladder; Lane A, D, and G: Val/Val; Lane B, E, and H: Met/Met; Lane C, F,
Figure 4 Agarose gel eletrophoretogram of 5-HT1A C-1019G
PCR product after digestion with Hpy CH4IV. The distribution of
the 5-HT1A C-1019G polymorphism in the ABB group, nABB group
and control group were in agreement with the Hardy-Weinberg
equilibrium. There were no significant differences between groups
(P > 0.05). Lane M: 50 bp DNA Ladder; Lane A: CG; Lane B: CC;
Lane C: GG.
Table 2 Genotype distribution (n (%)) of T102C and
A-1438G polymorphisms of the 5-HT2A gene among ABB
patients and healthy volunteers
102 TT 102 TC 102 CC
ABB group (n= 106)
−1438 AA 31(29.2) 3(2.8)
−1438 AG 3(2.8) 62(58.5) 2(1.9)
−1438 GG 3(2.8) 2(1.9)
Control group (n= 50)
−1438 AA 18(36.0)
−1438 AG 1(2.0) 20(40.0)
−1438 GG 11(22.0)
Yusup et al. BMC Complementary and Alternative Medicine 2013, 13:332 Page 7 of 11
http://www.biomedcentral.com/1472-6882/13/332statistical differences in the 5-HT1A C-1019G genotype
distributions among the ABB group, nABB group, and
control group (χ2= 14.633, P= 0.006). Compared with the
control and nABB groups, the ABB group had significant
differences (χ2= 7.703, P= 0.021; χ2= 13.387, P= 0.001) in
the 5-HT1A C-1019G genotype distributions. Compared
to the control group, the nABB group had not signifi-
cant differences (P > 0.05) in the 5-HT1A C-1019G geno-
type distributions. Individuals with the GG (OR 0.157;
95% CI 0.052 ~ 0.475) genotypes were more likely to not
have depression. Moreover, GG genotype seemed to be
protective factor. There were significant differences in
the 5-HT1A C-1019G allele distributions among the
ABB,nABB and control group (χ2= 7.914, P= 0.019).
Interaction analysis between the 5-HT2A T102C and
5-HT2A A-1438G polymorphisms in ABB patients and
healthy volunteers
The two polymorphisms were in linkage disequilibrium.
Table 2 shows that 93.3% of ABB and 78.0% of controls
homozygous for 102 T were also homozygous for -1438A.
In addition, 65.1% of ABB and 62.0% of controls homozy-
gous for 102C were also homozygous for -1438G allele.
The -1438A and 102 T allele frequencies were higher
among ABB (0.64 and 0.64, respectively) than in controls(0.57 and 0.58, respectively). The OR associated with the
presence of -1438A plus 102 T alleles was 3.989 for ABB
compared with controls (OR 3.989; 95% CI 1.442 ~
11.035; P= 0.005) (Table 2).
Interaction analysis between the BDNF Val66Met and
5-HT1A C-1019G polymorphisms in ABB patients and
healthy volunteers
Significant difference was observed between the ABB
and control groups (χ2= 14.692,P= 0.000) in the BDNF
Val66Met allele distribution. The Val allele was associ-
ated with 2.593 fold increased risk for depression com-
pared with Met allele (OR 2.593; 95% CI 1.583 ~ 4.249).
Moreover, there was a significant difference in the 5-HT1A
C-1019G allele distribution between the ABB and control
groups (χ2= 7.884,P= 0.005). The C allele was associated
with 2.006 fold increased risk for depression compared
with G allele (OR 2.006; 95% CI 1.229 ~ 3.271).
The OR associated with the combination of Val66Met-
Val/Val genotype plus the presence of -1019C allele was
8.393 for ABB compared with controls (OR 8.393; 95%
CI 1.807 ~ 38.991; P= 0.003). Moreover, the OR associ-
ated with the presence of -Met plus -1019C alleles was
12.194 for ABB compared with controls (OR 12.194;
95% CI 1.433 ~ 103.776; P= 0.005). The OR associated
with the presence of -1438C/C plus Val/Val genotypes
was 7.738 for ABB compared with controls (OR 7.738;
95% CI 1.566 ~ 38.241; P= 0.005) (Table 3).
Identification of independent risk factors for ABB
Table 4 presents the estimated logistic regression coeffi-
cients, estimated SEs, adjusted odds ratios (ORs), and
95% confidence intervals (CIs) for the adjusted ORs for
the final model for admissions. After adjusting for those
conventional depression risk factors such as age, gender,
the AA (of the A-1438G polymorphisms of the 5-HT2A
gene), Val/Val (of the Val66Met polymorphisms of the
BDNF gene), CC (of the C-1019G polymorphisms of the
5-HT1A gene) genotype still had an approximately. A
Table 3 BDNF Val66Met (5-HT1A C-1019G) genotype frequency in ABB patients and healthy volunteers according to
5-HT1A C-1019G (BDNF Val66Met) genotype
Genotypes Genotype frequency (n (%)) P value OR(95% CI)
ABB group (n= 106) Control group (n= 50)
Val66Met C-1019G
Val/Val CC 25(49.0) 2(16.7) 0 1
CG 22(43.2) 5(41.7)
GG 4(7.8) 5(41.7) 8.393(1.807 ~ 38.991)
Met/Val + Met/Met CC 21(38.2) 13(34.2) 0.01 1
CG 33(60.0) 18(47.4)
GG 1(1.8) 7(18.4) 12.194(1.433 ~ 103.776)
C-1019G Val66Met
CC Val/Val 25(54.3) 2(13.3) 0.01 1
Met/Val + Met/Met 21(45.7) 13(86.7) 7.738(1.566 ~ 38.241)
CG Val/Val 22(40.0) 5(21.7) 0.12 1
Met/Val + Met/Met 33(60.0) 18(78.3) 2.400(0.777 ~ 7.416)
GG Val/Val 4(80.0) 5(41.7) 0.15 1
Met/Val + Met/Met 1(20.0) 7(58.3) 5.600(0.472 ~ 66.447)
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factors: Gender (OR= 0.365, 95% CI: 0.136-0.982; P < 0.05),
Age (OR= 4.806, 95% CI: 2.476-9.328; P < 0.01), AA
(OR=13.759, 95% CI: 2.225-85.076; P <005; for 5-HT2A
A-1438G), Val/Val (OR= 39.791, 95% CI: 5.365-295.110;
P <0.01), CC (OR= 7.309, 95% CI: 1.349-39.597; P <0.05;
for 5-HT1A C-1019G). In addition, we found Val/Met
genotype of the BDNF Val66Met gene is also an independ-
ent risk factor for ABB with an odds ratio of 6.854-fold
higher relative risk of developing ABB than those with the
Met/Met homozygote (OR= 6.854, 95% CI: 1.092-43.033;
P < 0.05), also AG (OR=32.889, 95% CI: 4.981-217.178;
P < 0.01; for 5-HT2A A-1438G) and CG (OR= 7.420, 95%Table 4 Results of logistic analysis
ABB
B S.E. Wald P OR 95% C.I.
Gender −1.01 0.51 3.98 0.05 0.37 0.136-0.982
Age 1.57 0.34 21.52 0 4.81 2.476-9.328
A1438G(GG) 13.36 0
A1438G(AA) 2.62 0.93 7.95 0.01 13.76 2.225-85.076
A1438G(AG) 3.49 0.96 13.16 0 32.89 4.981-217.178
BDNF(Met/Met) 15.37 0
BDNF(Val/Val) 3.68 1.02 12.98 0 39.79 5.365-295.110
BDNF(Val/Met) 1.93 0.94 4.22 0.04 6.85 1.092-43.033
5-HT1A(GG) 5.74 0.06
5-HT1A(CC) 1.99 0.86 5.32 0.02 7.31 1.349-39.597
5-HT1A(CG) 2 0.9 5 0.03 7.42 1.282-42.965
Constant −7.28 1.66 19.21 0 0CI: 1.282-42.965; P < 0.05; for 5-HT1A C-1019G) genotypes
are an independent risk factor for ABB.
Discussion
Traditional Uighur Medicine (TUM), a well-known med-
ical system in China for their remarkable curative effect, is
based on the concept of equilibrium and balance of
natural body humors (blood, phlegm, yellow bile, and
black bile). The imbalance in the quality and quantity of
these humors leads to diseases whereas restoration of this
balance maintains health of a person [10]. Abnormal
humors include abnormal blood, abnormal phlegm, ab-
normal yellow bile and abnormal black bile. According to
TUM, abnormal black bile is a special humor in the body,
and is the main cause of complex diseases such as tumors,
diabetes mellitus, hypertension, and depression [12].
In this study, we evaluated the individual and interaction
effects of depression related gene polymorphisms in
depression with abnormal humor. Our results indicated
that there were significant interactions of the T102C and
A1438G SNPs in 5-HT2A receptor gene, Val66Met SNP in
BDNF gene, and C-1019G SNP in 5-HT1A receptor gene
with depression with abnormal humor. Moreover, the
present study showed a significant interaction between the
BDNF Val66Met and 5-HT1A C-1019G polymorphisms.
The present study on ABB revealed significant differ-
ence in the prevalence of 5-HT2A T102C and 5-HT2A
A-1438G genotype frequency compared with that of
controls and nABB patients. These results reported here
in a Chinese population were not in agreement with
those reported by Dawei Li, who found no association of
the T102C polymorphism with either schizophrenia or
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only detected between the A-1438G polymorphism and
suicidal behavior [30]. Our results failed to confirm
previous reports that genotype frequencies of 102 T/C
5-HT2A receptor gene polymorphism in mood disorders
do not differ from healthy volunteers [31-33]. Moreover,
Ho-kyoung Yoon concluded that the 5-HT2A T102C
polymorphism may not be associated with susceptibility
to suicidal behavior in Korean population [34]. We pos-
tulate that the differences in the genotype frequencies
between our study and previous reports may be the
result of ethnic differences of patients participated in
these studies. Furthermore, no difference was found in
5-HT2A T102C genotype and allele distribution between
the mood disordered subjects, with and without suicide
attempt history, and controls [35]. The authors con-
cluded that their study did not support the association
of the 5-HT2A gene with either schizophrenia or suicidal
behavior. The results showed a higher frequency of 5-
HT2A –1438A and 102 T alleles in ABB compared to
controls. We found that the 1438G, 102 T alleles and
the homozygosity for these alleles were significantly
more frequent among the patients with ABB than
among the controls, suggesting that the allele is associ-
ated with susceptibility to depression. We also found
that AA (or TT) genotype is an independent risk factor
for ABB according to the multiple logistic regression
models.
In this study, we found a significant difference among
the Val/Val, Val/Met, and Met/Met genotypes or
between Val and Met alleles in ABB group patients com-
pared with the controls and nABB patients. Our results
reported here in a Chinese population are in agreement
with those reports such as BDNF may have a major role
in the pathogenesis and treatment response of depres-
sion [36]. Two meta-analyses have suggested that BDNF
is associated with depression or the response to antide-
pressants [37,38], while another meta-analysis showed
no association [39]. In this study, ABB individuals with
the major allele (Val/Val) had an odds ratio of 2.9, also
Val/Val genotype is an independent risk factor for ABB
according to the multiple logistic regression models.
Our results confirmed previous reports that BDNF poly-
morphism is associated with increased risk of depression
in some studies [40,41], as some studies found no asso-
ciation [18,42-44]. In our study Val allele has a higher
distribution in the Chinese population, and Val/Val
genotype or carrying Val allele of BDNF Val66Met
polymorphism is associated with higher response to
depression. Approximately 30%-50% of people world-
wide are either heterozygous (Val/Met) or homozygous
(Met/Met) for the methionine substitution [45]. Although
there is a wealth of information about individuals hetero-
zygous for the Met polymorphism, little information existsabout individuals who are homozygous for the Met allele
(Met/Met), because this genotype is rare in the general
population, comprising only 4% of people in the United
States [45]. In studies of brain morphometry using
structural MRI scans,Val/Met individuals have repeatedly
been shown to have a smaller hippocampal volume rela-
tive to controls to who are homozygous for the Val allele
(Val/Val) [46,47]. This difference may be related to the
role BDNF and its receptors play in the development as
well as continued plasticity of the brain [48,49].
In this study, we found a significant difference between
5-HT1A gene CC, CG, and GG genotype or between C
and G allele in ABB group patients compared with the
controls and nABB patients. We found that the CC allele
and the homozygosity for this allele were significantly
more frequent among the patients with ABB than among
the controls, suggesting that the allele is associated with
susceptibility to depression. Our results were not in agree-
ment with these reports that GG genotype is associated
with increased risk of depression [22] and suicide [21]. In
our study C allele has a higher distribution in the Chinese
population, and CC genotype or carrying C allele of 5-
HT1A C1019G gene is associated with higher response to
depression patients with abnormal humor syndrome. We
also found that ABB individuals with the major allele (CC)
had an odd ratio of 1.8; CC genotype is an independent
risk factor for ABB according to the multiple logistic
regression models.
In the present study, subjects carrying both 5-HT1A
C1019G polymorphism CC genotype and Val/Val geno-
type of BDNF Val66Met polymorphism had over seven
times higher risk of depression than those who did not
have this combination of polymorphisms. We reported a
significant association between combined polymorphisms
of 5-HT1A and BDNF polymorphisms and our result was
in line with earlier reports [50].
In summary, the present study demonstrated that the
A-1438 and T102C polymorphisms of the 5-HT2A recep-
tor gene, BDNF Val66Met, and 5-HT1A C-1019G might
predict the incidence of depression induced by abnormal
black bile. The results showed a higher frequency of 5-
HT2A –1438A and 102 T alleles. 5-HT2A –1438A and
102 T polymorphisms were in linkage disequilibrium.
ABB individuals with the major allele (Val/Val) had a
three times of odds ratio, also ABB individuals with the
major allele (CC) had a two times of odds ratio. The AA,
Val/Val, and CC genotypes were independent risk factors
for the ABB. There was a significant association between
combined polymorphisms of 5-HT1A and BDNF poly-
morphisms. However, it was the first study to investi-
gate the association of multiple gene polymorphisms
and depression with abnormal humor in TUM. Of
course, as an ancient medical system, principles of
TUM classification of depression contain a variety of
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to provide new ideas for individualized diagnosis, pre-
vention, treatment of depression.
Conclusions
It was concluded that there were significant relationship
between the gene polymorphisms and classification of
depression with abnormal humor in TUM. The 5-HT2A
A-1438G, 5-HT2A T102C, BDNF Val66Met, and 5-HT1A
C-1019G gene polymorphisms might predict the inci-
dence of depression with ABB. It was the first study to
investigate the association of multiple gene polymor-
phisms and depression with abnormal humor in TUM. Of
course, as an ancient medical system, principles of TUM
classification of depression contain a variety of biological
foundation. But the present study at least to provide new
ideas for individualized diagnosis, prevention, treatment
of depression.
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